Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 3rd Annual series of webcast "RNAi Roundtables" this summer and early fall. The 2016 series will consist of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company's development-stage pipeline programs. Each event will be webcast live on the Investors page of the Company's website, www.alnylam.com, and a replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
The first roundtable of the series will focus on patisiran and revusiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This event will take place on Wednesday, July 20, 11:30 a.m. - 1:00 p.m. ET. Featured speakers include:
- Eric Green, Vice President, General Manager, TTR Program
- Jared Gollob, M.D., Vice President, Clinical Research
- Guest Speaker: John L. Berk, M.D., Director, Clinical Trials for Familial Amyloidosis and Director, Localized Amyloid Clinic, Boston University Amyloidosis Center
- Guest Speaker: Christina Lindsey, Patient living with hATTR amyloidosis
The second roundtable will focus on fitusiran for the treatment of hemophilia and rare bleeding disorders. This event will take place on Monday, August 22, 10:30 a.m. - 12:00 p.m. ET. Featured speakers include:
- Akin Akinc, Ph.D., Vice President, General Manager, Fitusiran Program
- Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development
- Guest Speaker: Brian O’Mahony, Chief Executive, Irish Haemophilia Society Ltd. and person living with severe hemophilia B
Alnylam has scheduled additional RNAi Roundtables in the coming months focused on some of its other clinical programs, including: ALN-CC5 for the treatment of complement-mediated diseases, ALN-AS1 for the treatment of acute hepatic porphyrias, ALN-GO1 for the treatment of primary hyperoxaluria type 1 and ALN-HBV for the treatment of hepatitis B virus infection.
Additional details for the rest of the RNAi Roundtables, including speakers, dates and times will be provided on the Capella section of the Company's website, www.alnylam.com/capella.
About RNAi
RNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as "a major
scientific breakthrough that happens once every decade or so," and
represents one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel Prize
for Physiology or Medicine. RNAi is a natural process of gene silencing
that occurs in organisms ranging from plants to mammals. By harnessing
the natural biological process of RNAi occurring in our cells, the
creation of a major new class of medicines, known as RNAi therapeutics,
is on the horizon. Small interfering RNA (siRNA), the molecules that
mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target
the cause of diseases by potently silencing specific mRNAs, thereby
preventing disease-causing proteins from being made. RNAi therapeutics
have the potential to treat disease and help patients in a fundamentally
new way.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical
company developing novel therapeutics based on RNA interference, or
RNAi. The company is leading the translation of RNAi as a new class of
innovative medicines. Alnylam's pipeline of investigational RNAi
therapeutics is focused in 3 Strategic Therapeutic Areas (STArs):
Genetic Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of
RNAi therapeutics toward genetically validated, liver-expressed disease
targets for unmet needs in cardiovascular and metabolic diseases; and
Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance
for the advancement and commercialization of RNAi therapeutics as a
whole new class of innovative medicines. Specifically, by the end of
2020, Alnylam expects to achieve a company profile with 3 marketed
products, 10 RNAi therapeutic clinical programs – including 4 in late
stages of development – across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major alliances
with leading companies including Ionis, Novartis, Roche, Takeda, Merck,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a company
focused on discovery, development, and commercialization of microRNA
therapeutics. Alnylam scientists and collaborators have published their
research on RNAi therapeutics in over 200 peer-reviewed papers,
including many in the world's top scientific journals such as Nature,
Nature Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information about
Alnylam's pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160712005405/en/
Contacts:
(Investors and Media)
Christine
Regan Lindenboom, 617-682-4340
or
(Investors)
Josh
Brodsky, 617-551-8276